Company intelligence / Profile preview

usMIMA

Barcelona, Catalonia, Spain

Ownership: Private
Development stage: Other

Overview

Clinical studies have demonstrated that MOWOOT provides significant benefits to severely constipated patients, showing higher efficacy than current remedies with only daily use of about 20 minutes. The therapy improves quality of life without side effects associated with pharmacological treatments. The FDA Breakthrough Device Designation highlights its potential advantages over existing alternatives.

Therapeutic areas: GastroenterologyNeurology
Modalities: Medical DeviceNon-pharmacological therapy device
Industry: Therapeutic Medical Devices

Partnerships

Institut GuttmannBiocat’s MOEBIO EU Stanford Biodesign programDistribution agreements in Germany, England, Netherlands, Denmark

Beyond the preview

Go deeper on usMIMA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on usMIMA.

Explore the full profile